克拉珠利 | 101831-36-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 克拉珠利
• 中文别名: 氯腈索利
• 英文名称: 2-chloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitrile
• 英文别名: clazuril；2-chloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-phenylacetonitrile；2-[2-chloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]-2-(4-chlorophenyl)acetonitrile
• CAS: 101831-36-1
• 化学式: C₁₇H₁₀Cl₂N₄O₂
• 分子量: 373.198
• InChiKey: QUUTUGLQZLNABV-UHFFFAOYSA-N

物化性质

• 熔点：
  196.8°
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

氯化尿利（R62690）对两种艾美耳球虫的无性和有性发育阶段均有杀球虫作用，从而完全中断其生活周期。

反应信息

• 作为反应物：
  描述：

  克拉珠利 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 2-chloro-α-(4-chlorophenyl)-4-(3,4,5,6-tetrahydro-3,5-dioxo-1,2,4-triazin-2(1 H)-yl)benzeneacetonitrile
  参考文献：
  名称：

  Anti-protozoal 5,6-dihydro-2-(substituted

  摘要：

  一种在患有原虫病的受试者中有效地破坏或预防原虫生长的新型5,6-二氢-2-(取代苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮。

  公开号：

  US04767760A1
• 作为产物：
  描述：

  2-[3-chloro-4-[chloro(4-chlorophenyl)methyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione 以 甲醇 、 四氯化碳 、 氯仿 、 乙腈 为溶剂， 以1.3 parts (11.2%)的产率得到克拉珠利
  参考文献：
  名称：

  Anti-protozoal

  摘要：

  本发明涉及对受到原生动物感染的患者进行破坏或预防原生动物生长的α-芳基-4-(4,5-二氢-3,5-二氧化-1,2,4-三嗪-2(3H)-基)苯乙腈。

  公开号：

  US04631278A1

文献信息

• [EN] N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS N-HÉTÉROARYLÉS AYANT UNE UNITÉ PONTANTE CYCLIQUE POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：INTERVET INT BV

  公开号：WO2012041872A1

  公开（公告）日：2012-04-05

  This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of the N-heteroaryl compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  这项发明涉及某些N-杂环芳基化合物，通常用作药物，更具体地用作动物药物。该药物可以优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。该发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物用于需要治疗的动物的给药。此外，该发明还涉及N-杂环芳基化合物的制备。此外，该发明还涉及包含这些化合物的药物组合物和试剂盒。
• INSECTICIDAL, MITICIDAL, NEMATICIDAL, MOLLUSCICIDAL, MICROBICIDAL, OR BACTERICIDAL COMPOSITION AND METHOD FOR CONTROLLING PEST
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US20170135347A1

  公开（公告）日：2017-05-18

  The present invention provides a novel insecticidal, miticidal, nematicidal, microbicidal, or bactericidal composition and a novel pest control method. An insecticide, miticide, nematicide, molluscicide, disinfectant, or bactericide composition containing one or two substances selected from 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)isoxazole-3-yl]-2-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]benzamide or (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazole-3-yl]-N-(methoxyiminomethyl)-2-methylbenzamide, and one or more substances selected from known insecticide, miticide, nematicide, molluscicide, disinfectant, or bactericide compounds.

  本发明提供了一种新型的杀虫、杀螨、杀线虫、杀微生物或杀菌组合物以及一种新型的害虫控制方法。一种杀虫剂、杀螨剂、杀线虫剂、杀软体动物剂、消毒剂或杀菌剂组合物，包含从4-[5-(3,5-二氯苯基)-4,5-二氢-5-(三氟甲基)异噁唑-3-基]-2-甲基-N-[2-氧代-2-[(2,2,2-三氟乙基)氨基]乙基]苯甲酰胺或(Z)-4-[5-(3,5-二氯苯基)-5-三氟甲基-4,5-二氢异噁唑-3-基]-N-(甲氧亚胺甲基)-2-甲基苯甲酰胺中选择的一种或两种物质，以及从已知的杀虫剂、杀螨剂、杀线虫剂、杀软体动物剂、消毒剂或杀菌剂化合物中选择的一种或多种物质。
• Novel IL-5 inhibiting 6-azauracil derivatives
  申请人：——

  公开号：US20020072603A1

  公开（公告）日：2002-06-13

  The present invention is concerned with the compounds of formula 1 the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, p and q are 0, 1, 2, 3 or 4 and q is also 5; X is O, S, NR 3 or a direct bond; R 1 is hydrogen, hydroxy, halo, optionally substituted amino, optionally substituted C 1-6 alkyl, C 1-6 alkyloxy, C 3-7 cycloalkyl or aryl; R 2 is aryl, Het 1 , C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl; and if X is O, S or NR 3 , then R 2 may also be a carbonyl or thiocarbonyl linked substituent; R 3 is hydrogen or C 1-4 alkyl; R 4 and R 5 independently are optionally substituted C 1-6 alkyl, halo, hydroxy, mercapto, C 1-6 alkyloxy, C 1-6 akylthio, C 1-6 alkylcarbonyloxy, aryl, cyano, nitro, Het 3 , R 6 or NR 7 R 8 ; R 6 is substituted sulfonyl or sulfinyl; R 7 and R 8 are hydrogen, optionally substituted C 1-4 alkyl, aryl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 9 and R 10 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 11 is hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C 1-4 alkyloxy, carboxyl, C 1-4 alkyloxycarbonyl, trihaloC 1-4 alkylsulfonyloxy, R 6 , NR 7 R 8 , C(═O)NR 7 R 8 , aryl, aryloxy, arylcarbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, phthalimide-2-yl, Het 3 and C(═O)Het 3 ; R 12 and R 13 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl and R 6 ; aryl is optionally substituted phenyl; Het 1 , Het 2 and Het 3 are optionally substituted heterocycles; to processes for their preparation and compositions comprising them. It further relates to their use as a medicine.

  本发明涉及公式1的化合物，包括N-氧化物、药学上可接受的加合盐以及其立体化异构体形式，其中p和q为0、1、2、3或4，q也可以为5；X为O、S、NR3或直接键；R1为氢、羟基、卤素、可选择取代的氨基、可选择取代的C1-6烷基、C1-6烷氧基、C3-7环烷基或芳基；R2为芳基、Het1、C3-7环烷基、可选择取代的C1-6烷基；如果X为O、S或NR3，则R2也可以是羰基或硫代羰基连接的取代基；R3为氢或C1-4烷基；R4和R5独立地为可选择取代的C1-6烷基、卤素、羟基、巯基、C1-6烷氧基、C1-6烷硫基、C1-6烷基羰氧基、芳基、氰基、硝基、Het3、R6或NR7R8；R6为取代磺酰基或亚砜基；R7和R8为氢、可选择取代的C1-4烷基、芳基、羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R9和R10各自独立地选自氢、可选择取代的C1-4烷基、苯基、羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R11为羟基、巯基、氰基、硝基、卤素、三卤甲基、C1-4烷氧基、羧基、C1-4烷氧羰基、三卤代C1-4烷基磺酰氧基、R6、NR7R8、C(═O)NR7R8、芳基、芳氧基、芳基羰基、C3-7环烷基、C3-7环烷氧基、邻苯二甲酰亚胺-2-基、Het3和C(═O)Het3；R12和R13各自独立地选自氢、可选择取代的C1-4烷基、苯基、羰基或硫代羰基连接的取代基、C3-7环烷基和R6；芳基为可选择取代的苯基；Het1、Het2和Het3为可选择取代的杂环；以及其制备方法和包含它们的组合物。进一步涉及它们作为药物的用途。
• [EN] NOVEL SPIROINDOLINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE SPIROINDOLINE
  申请人：INTERVET INT BV

  公开号：WO2013017678A1

  公开（公告）日：2013-02-07

  This invention relates to novel spiroindoline compounds of formula (I) that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  本发明涉及一种新型螺环吲哚烷化合物，通式为(I)，通常用作药物，更具体地用作动物药物。该药物可用于治疗蠕虫感染和寄生虫病的治疗，比如由蠕虫感染引起的寄生虫病。本发明还涉及利用这些化合物制备药物和治疗方案，包括将这些化合物用于需要治疗的动物。此外，本发明还涉及所述化合物的制备。此外，本发明还涉及包含这些化合物的药物组合物和工具包。
• [EN] ANTHELMINTIC COMPOUNDS COMPRISING A QUINOLINE STRUCTURE<br/>[FR] COMPOSÉS ANTHELMINTHIQUES COMPRENANT UNE STRUCTURE DE QUINOLÉINE
  申请人：INTERVET INT BV

  公开号：WO2021122911A1

  公开（公告）日：2021-06-24

  The present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria, in particular Dirofilaria immitis.

  本发明涉及新的驱虫化合物。这些化合物可以用于治疗由蛔虫等寄生虫引起的蠕虫病，例如 Dirofilaria，特别是 Dirofilaria immitis。